T he renin-angiotensin system has a central role in the regulation of blood pressure and water balance. It is also a main target in the treatment of hypertension. Angiotensin II has 2 major receptors, the type 1 (AT 1 R) and the type 2 receptor (AT 2 R), both coupled to G proteins. Adverse vascular remodeling observed in cardiovascular diseases is attributed to AT 1 R, and a large number of relatively selective AT 1 R inhibitors are now used in patients. The effects of AT 2 R are usually presented as counteracting the effects exerted by AT 1 R. Consequently, some beneficial effects of the AT 1 R blockers (angiotensin receptor blocker) are commonly attributed to AT 2 R activation.
T he renin-angiotensin system has a central role in the regulation of blood pressure and water balance. It is also a main target in the treatment of hypertension. Angiotensin II has 2 major receptors, the type 1 (AT 1 R) and the type 2 receptor (AT 2 R), both coupled to G proteins. Adverse vascular remodeling observed in cardiovascular diseases is attributed to AT 1 R, and a large number of relatively selective AT 1 R inhibitors are now used in patients. The effects of AT 2 R are usually presented as counteracting the effects exerted by AT 1 R. Consequently, some beneficial effects of the AT 1 R blockers (angiotensin receptor blocker) are commonly attributed to AT 2 R activation. 1 Beneficial vascular effects of AT 2 R have now been proven by several studies. For example, AT 2 R stimulation reduces vascular RhoA/Rho kinase/myosin light chain phosphorylation in angiotensin II and AT 1 R antagonist valsartan-treated vascular smooth muscle cells in vitro, as well as in the aorta of spontaneously hypertensive rats chronically treated with candesartan.
2 Altogether, previous studies suggest a role for vascular AT 2 R in blood pressure lowering during chronic AT 1 R blockade. Similarly, in hypertensive diabetic patients, chronic angiotensin receptor blocker treatment increases AT 2 R expression level and AT 2 R-dependent vasodilatation of mesenteric resistance arteries. 3 Nevertheless, in the absence of AT 1 R inhibition, expression of AT 2 R varies a lot under physiological and pathophysiological conditions, 4 and the relatively low selectivity of the antagonist PD123319 and the weak specificity of the agonist CGP42112 do not help fully understand the role of AT 2 R. Thus, its role in most cardiovascular and metabolic disorders remains poorly understood and mainly hypothetical.
Consequently, the availability of the first nonpeptide AT 2 R agonist, compound 21 (C21), was seen as a major breakthrough, as described in a recent review article. 1 Indeed, C21 has protective effects after myocardial infarction and in hypertension-induced end organ damage. In different animal models, AT 2 Rs also display an anti-inflammatory effect. 1 Nevertheless, there is accumulating evidence that the commonly accepted scheme with a balance between a constrictor effect of AT 1 R and a dilator effect of AT 2 R is too simplistic and does not always reflect experimental evidence. The work performed by Verdonk et al, 5 published in this issue of Hypertension, on the AT 2 R agonist C21 further highlights the complexity of this system, in addition to bringing key information on the mechanism of action of this new drug. Although C21 binds to AT 2 R with high affinity, this study also shows that C21 induces a puzzling combination of vasodilation and vasoconstriction. Surprisingly, C21-mediated vasodilation was independent of AT 2 R and of the endothelium. Indeed, the authors have shown that C21 has a direct inhibitory effect on calcium influx into smooth muscle cells, thus leading to relaxation. C21 was tested in rat and mouse arteries, as well as human coronary arteries, and C21-dependent vasodilation through calcium entry inhibition was also observed in mice lacking the gene encoding for AT 2 R. Furthermore, in the isolated perfused heart, C21 induces an initial AT 1 R-dependent contraction followed by AT 2 R-independent dilatation. The constrictor effect of AT 2 R was more pronounced in hypertensive rats, as shown previously. 6 This article brings up 2 major issues requiring further discussion. First, C21-dependent dilatation relies mainly on calcium entry blockade without interfering with the RhoARho-kinase pathway, which has been shown to be inhibited after AT 2 R stimulation. This finding requires reanalysis of the studies showing protective effects of C21. Indeed, the organ-protective effect of C21 is compatible with the effects of the dihydropyridine calcium channel blockers, that is, reduction of proliferation, inflammation, fibrosis, and vasoconstriction. The authors also show that low doses C21 are needed to selectively block AT 2 R. Lower doses of C21 might be used after AT 1 R blockade, which induces a large increase in AT 2 R expression level. In this condition, lower doses of C21 might be sufficient to more selectively block AT 2 R. Lower-dose C21 could, thus, be useful in resistant hypertension, although in this case its effect on calcium currents might also be advantageous. Low-dose C21 might also provide additional protection against organ damage in kidney and heart diseases in patients treated with angiotensin receptor blockers. Nevertheless, no data are yet available to support this assumption. It should be noted that more and more patients, not only hypertensive patients, receive angiotensin receptor blockers. In these conditions, a better knowledge of the effect of AT 2 R stimulation is essential, especially in the different organs affected by cardiovascular diseases. Second, this work further confirms with straightforward experiments the complexity of AT 2 R physiopathology. That AT 2 R stimulation induces dilatation or contraction depending on the type of artery or on the disease makes it difficult to use tools targeting this receptor.
Indeed, the findings of this article raise several important questions, the answers to which await further investigation. First, is there enough AT 2 R to be stimulated in the absence of AT 1 R blockade or in the absence of other factors increasing AT 2 R expression level and, second, is the effect of AT 2 R stimulation enough predictable. Although AT 2 R do not seem to desensitize, its stimulation does not induce important dilatation, and, in some cases, vasoconstriction may occur as observed in hypertensive 6 or in aged rats. 7 Furthermore, AT 2 R-dependent dilatation may be stronger and perhaps more persistent in female than in male rats. 8 However, in the present study, coronary arteries from 2 men and 3 women were used without obvious difference attributed to gender, so more attention should be given in future studies to a possible sex difference in the effects of AT 2 R stimulation. Indeed, AT 2 R may have a role, other than the estrogen receptors, in the protection against cardiovascular events provided by female hormones before menopause. Of course, this very hypothetical issue remains to be further investigated.
That the effect of AT 2 R stimulation varies so much according to tissue type, age, sex, or diseases remains puzzling. Nevertheless, a more direct interaction between receptors may provide, at least in part, an explanation. Indeed, AT 2 R-AT 1 R dimerization might occur and affect the consecutive signal transduction. Although this concept still lacks functional evidence, receptor dimerization should be taken into account in future studies, especially because it may affect receptor internalization and intracellular signaling. Internalization of AT 2 R does not seem to occur, whereas AT 1 R internalization follows rapidly its stimulation. 9 Consequently AT 2 R-AT 1 R heterodimerization might affect, and eventually prevent, AT 1 R intracellular signaling. Finally, although the role of internalized AT 1 R is not yet fully understood, angiotensin II receptor, AT 1 R, AT 2 R, and AT 7 R, have been identified in the nucleus and in mitochondria. 10 Once again, the AT 2 R differs from the other receptors because it lacks the canonical nuclear localization sequence. Nevertheless, in isolated nuclear or mitochondrial fractions, AT 2 R stimulation with CGP4211A induces NO production, which is suppressed by PD123319 and by N G -nitro-L-arginine methyl ester. 10 Although the role of this nuclear reninangiotensin system remains mainly unknown, it may add to the diversity of the effects of AT 2 R stimulation and hopefully help in better understanding its physiology.
Thus, reinterpretation of recently published articles using C21 in animal models of cardiovascular diseases is required. Nevertheless, it remains that C21 has beneficial effects against organ damage, although the precise mechanism of action is now less clear. Indeed, unlike C21, many commonly prescribed drugs are not well known, and their mechanism of action remains a matter of debate. Most importantly, much remains to be discovered concerning the role of AT 2 R and the mechanisms involved in the cardiovascular system.
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